Table 3

General and sex-specific HRs for the relationship between percentage of target dose and all-cause mortality stratified by HF subtype

All HF subtypesHFrEFHFpEF
Crude HR
(95% CI)
Adjusted HR
(95% CI)
Crude HR
(95% CI)
Adjusted HR
(95% CI)
Crude HR
(95% CI)
Adjusted HR
(95% CI)
Whole cohort
ACEI/ARB
 <50% of target dose1.07 (0.81 to 1.42)
p=0.62
1.01 (0.76 to 1.33)
p=0.96
0.71 (0.47 to 1.07)
p=0.10
0.63 (0.42 to 0.96)
p=0.03
0.92 (0.50 to 1.68)
p=0.79
1.02 (0.57 to 1.84)
p=0.94
 ≥50% of target dose (ref)111111
Beta blockers
 <50% of target dose1.00 (0.75 to 1.35)
p=0.97
1.05 (0.78 to 1.41)
p=0.75
0.91 (0.57 to 1.45)
p=0.68
0.99 (0.62 to 1.59)
p=0.96
1.17 (0.62 to 2.21)
p=0.63
1.27 (0.69 to 2.35)
p=0.44
 ≥50% of target dose (ref)111111
Women
ACEI/ARB
 <50% of target dose1.07 (0.70 to 1.63)
p=0.76
1.05 (0.69 to 1.60)
p=0.82
0.54 (0.28 to 1.03)
p=0.06
0.49 (0.25 to 0.99)
p=0.05
0.70 (0.30 to 1.64)
p=0.41
0.75 (0.32 to 1.73)
p=0.50
 ≥50% of target dose (ref)111111
Beta blockers
 <50% of target dose1.09 (0.71 to 1.66)
p=0.69
1.10 (0.72 to 1.68)
p=0.66
0.96 (0.47 to 1.95)
p=0.92
1.06 (0.51 to 2.20)
p=0.88
1.54 (0.72 to 3.29)
p=0.27
1.62 (0.77 to 3.40)
p=0.21
 ≥50% of target dose (ref)111111
Men
ACEI/ARB
 <50% of target dose1.10 (0.75 to 1.59)
p=0.63
1.00 (0.69 to 1.44)
p=0.98
0.88 (0.52 to 1.49)
p=0.64
0.76 (0.45 to 1.28)
p=0.30
1.35 (0.57 to 3.21)
p=0.50
1.48 (0.64 to 3.44)
p=0.36
 ≥50% of target dose (ref)111111
Beta blockers
 <50% of target dose0.93 (0.62 to 1.41)
p=0.74
1.00 (0.67 to 1.51)
p=0.98
0.88 (0.47 to 1.63)
p=0.68
0.95 (0.51 to 1.76)
p=0.86
0.62 (0.19 to 2.09)
p=0.44
0.75 (0.24 to 2.29)
p=0.61
 ≥50% of target dose (ref)111111
  • ACEI, ACE inhibitor; AR, angiotensin II receptor; ARB, angiotensin-receptor blocker; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ref, reference.